Identification and characterization of surgical samples from poor NAT responders also fostered the development of new neoadjuvant and adjuvant therapies, thereby improving patient outcomes compared with adjuvant treatments in the TN and HER2+ BC subtypes (7). Here, ERBB2 is linked to breast cancer.